ANECORTAVE ACETATE AS MONOTHERAPY FOR THE TREATMENT OF SUBFOVEAL LESIONS IN PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION (AMD): Interim (Month 6) Analysis of Clinical Safety and Efficacy
The DOI matches its Crossref record.
Abstract
PURPOSE: To evaluate clinical safety and efficacy of the angiostatic agent anecortave acetate for treatment of subfoveal choroidal neovascularization secondary to AMD. METHODS: 128 patients were randomized to placebo treatment or one of three anecortave acetate doses. Study medication was administered as a posterior juxtascleral injection onto the posterior scleral surface. Best-corrected logMAR vision was obtained at baseline and follow-up visits. Fluorescein angiograms were evaluated for eligibility before enrollment and posttreatment. RESULTS: Six months after a single treatment, visual acuity (mean change from baseline logMAR values) was significantly better (P = 0.003) after anecortave acetate 15 mg than placebo. More patients treated with anecortave acetate 15 mg than placebo maintained vision (88% versus 70%, P = 0.080), especially those with predominantly classic lesions (92% versus 65%, P = 0.021). Anecortave acetate 15 mg inhibited lesion growth significantly better than placebo (P = 0.001). Trends favoring the other doses over placebo were observed for vision preservation and lesion inhibition, but statistical significance was not achieved. The Independent Safety Committee overseeing this study identified no clinically relevant treatment-related changes. CONCLUSION: Anecortave acetate 15 mg is safe and effective for preserving or improving vision and for inhibiting lesion growth in patients with subfoveal AMD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Vascular endothelial growth factor in eye disease
Penn, J. S., Madan, A., Caldwell, R. B., Bartoli, M., Caldwell, R. W., & Hartnett, M. E. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.05.001 · Cited by 762
Grossniklaus, H. E., & Green, W. R. (2004) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2003.09.042 · Cited by 469
Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration
Ng, E. W. M., & Adamis, A. P. (2005) · Canadian Journal of Ophthalmology · doi:10.1016/s0008-4182(05)80078-x · Cited by 273
Pathogenesis of lesions in late age-related macular disease
Holz, F. G., Pauleikhoff, D., Klein, R., & Bird, A. C. (2004) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2003.11.026 · Cited by 203
Jiménez-Gómez, Y., Alba-Molina, D., Blanco-Blanco, M., Pérez-Fajardo, L., Reyes-Ortega, F., Ortega-Llamas, L., Villalba-González, M., Fernández-Choquet de Isla, I., Pugliese, F., Stoikow, I., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071473 · Cited by 19
Metadata
- Authors
- The Anecortave Acetate Clinical Study Group
- Venue
- RETINA
- Published
- 2003-02
- Volume
- 23
- Issue
- 1
- Pages
- 14-23
- ISSN
- 0275-004X (ISSN-L)
- OpenAlex
- W2416776471
- Cited by
- 96
- References
- 0
- FWCI
- 17.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ANECORTAVE ACETATE AS MONOTHERAPY FOR THE TREATMENT OF SUBFOVEAL LESIONS IN PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION (AMD): Interim (Month 6) Analysis of Clinical Safety and Efficacy. https://app.cochat.ai/papers/10.1097/00006982-200302000-00003
- The paper
- The Anecortave Acetate Clinical Study Group. (2003). ANECORTAVE ACETATE AS MONOTHERAPY FOR THE TREATMENT OF SUBFOVEAL LESIONS IN PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION (AMD): Interim (Month 6) Analysis of Clinical Safety and Efficacy. RETINA. https://doi.org/10.1097/00006982-200302000-00003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.